In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2% for aripiprazole-treated patients and 15.7% for placebo-treated patients.
Platseebokontrolliga pikaaegses 26 nädalase uuringu säilitusfaasis esines EPS 18, 2% aripiprasooli ja 15, 7% platseebot saanud patsientidest.